Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIETS trial: VATS versus intrapleural enzymatic therapy for empyema
2026-526289-25-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dornase alfa and tissue-plasminogen activator in pleural abscess, Empyema Thoracis and pneumonia (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Length of hospital stay within first 30 days. Planned start Oct 2026; status: authorised.
02
Drugs
dornase alfatissue-plasminogen activator
03
Conditions
pleural abscessEmpyema Thoracispneumonia
Beyond the preview
Go deeper on 2026-526289-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526289-25-00.